MedicineNews.net - Medical Updates


Sanofi and its subsidiary Genzyme have announced results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug Alemtuzumab ( Lemtrada ) to the approved multiple sclerosis therapy Rebif ( high dose subcutaneous Interferon beta-1a ) in patients with relapsing-remitting multiple sclerosis ( RRMS ).

In the CARE-MS I trial, 2 annual cycles of Alemtuzumab treatment resulted in a 55% reduction in relapse rate compared to Rebif over the two years of the study ( p